Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
The use of intraperitoneal radioisotopes in the management of women with ovarian cancer is controversial. We analyzed the experience with intraperitoneal chromic phosphate P 32 at our institution, from October 1979 to February 1983, in 22 patients with various stages and grades of ovarian malignancy. Survival in stage I is 87.5% and in stage II, 50%. Survival is 88.9% among patients with grade 1 tumors and 33.3% for those with grade 3 lesions. Morbidity related to chromic phosphate P 32 was minimal; small bowel obstruction occurred in only one patient who had also received external pelvic irradiation. Our results suggest that chromic phosphate P 32 is a safe, well tolerated, inexpensive, and effective adjuvant to surgery in the management of selected patients with ovarian malignancy.
Department of Gynecology, St. Joseph's Hospital, Atlanta, Ga.
J L
JL
Powell
M O
MO
Burrell
A B
AB
Kirchner
D000230:Adenocarcinoma / Q000532:radiotherapy*; D001918:Brachytherapy; D002857:Chromium / Q000627:therapeutic use*; D017608:Chromium Compounds; D003536:Cystadenocarcinoma / Q000532:radiotherapy*; D004715:Endometriosis / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D010710:Phosphates / Q000627:therapeutic use*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use
D017608:Chromium Compounds; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D002857:Chromium; C509369:chromic phosphate